Intravenous Thrombolysis With rhTNK-tPA for Acute Non-large Vessel Occlusion in Extended Time Window
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 570 participants.
Also called NCT05752916
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 570 participants
- Registry
-
NCT05752916
-
- Other papers using this trial's data
- Tenecteplase for Acute Non-Large Vessel Occlusion 4.5 to 24 Hours After Ischemic Stroke: The OPTION Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05752916. Randomized; single masking; primary purpose treatment. Start 2023-06-02 (actual); primary completion 2025-10-28 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Intravenous Thrombolysis With rhTNK-tPA for Acute Non-large Vessel Occlusion in Extended Time Window
- Acronym
- OPTION
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- rhTNK-tPA
- Intervention (Drug)
- Antiplatelet Agents
- Lead sponsor
- Xuanwu Hospital, Beijing
- Collaborator
- CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
- Collaborator
- Beijing Hospitals Authority
Record details
- Record id
cardio:ct-nct05752916- Content hash
b16c717b2c704e7d342b74578c43c73f1be92bc4de293800abcb4dd9b0814f2d